In our case, we showed that the novel QTAP-mRNA vaccine elicits predominantly CD4 T cell response during the early phases of infection whereas the late phase of infection is characterized by both CD4 and CD8 T cell response in vaccinated mice. Here, CD8A is linked to infection.